Medtronic Plc current report, 12 May 2020

Business Context and Reporting Period

This Form 8-K filing by Medtronic Plc (Medtronic) reports on events occurring on May 12, 2020. The filing details the entry into a material definitive agreement involving a new term loan facility.

Key Financial Metrics and Liquidity

  • New Debt Facility: Entered into a Term Loan Agreement for an aggregate principal amount of up to JPY 300,000,000,000 (approximately $300 billion JPY).
  • Loan Terms: Six-month term with an option to extend for an additional six months. Interest rate is TIBOR plus a margin of 0.50% per annum.
  • Borrowing Status: The entire amount of the term loan was borrowed on May 13, 2020.
  • Liquidity Position: As of the end of the third fiscal quarter, the Company held approximately $11 billion in cash and investments.
  • Existing Facilities: Maintains an undrawn $3.5 billion revolving credit facility.
  • Debt Maturity: No public debt matures until March 2021.

Material Changes

The primary material change is the creation of a direct financial obligation through the new JPY 300 billion term loan. This transaction was executed by Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), a wholly owned subsidiary, with guarantees provided by Medtronic plc and Medtronic, Inc. The proceeds are designated for general corporate purposes.

Management Commentary and Outlook

Management characterized the transaction as "opportunistic" due to the attractive terms of the Loan Agreement. The Company reiterated that it remains in a "strong financial position with ample liquidity." The filing does not provide specific revenue or profit guidance, nor does it detail specific risks beyond standard covenant language and customary representations.

Investor Verification Checklist

  • Verify the exact USD equivalent of the JPY 300,000,000,000 loan at the time of borrowing.
  • Confirm the specific impact of the new debt on the Company's leverage ratios in the next quarterly report.
  • Review the full text of the Term Loan Agreement (Exhibit 10.01) for specific affirmative and negative covenants.
  • Monitor the utilization of the $3.5 billion undrawn revolving credit facility.